Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. The company is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). The company has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Dr. Juan Vera is the President of Marker Therapeutics Inc, joining the firm since 2018.
What is the price performance of MRKR stock?
The current price of MRKR is $1.4, it has increased 4.47% in the last trading day.
What are the primary business themes or industries for Marker Therapeutics Inc?
Marker Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Marker Therapeutics Inc market cap?
Marker Therapeutics Inc's current market cap is $23.3M
Is Marker Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Marker Therapeutics Inc, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell